The Asia Pacific Metastatic Cancer Drugs Market would witness market growth of 8.3% CAGR during the forecast period (2023-2030).
The market is anticipated to expand due to initiatives to enhance awareness campaigns and screenings for metastatic cancer. Governments, healthcare providers, and advocacy groups may fund programs to motivate individuals to have routine screenings, which will help with the early identification of cases of metastatic cancer. This focus on early detection will result in a rise in demand for medications that treat metastatic cancer.
Pharmaceutical companies, academic institutions, and research organizations make substantial R&D investments to discover and develop innovative medicines for metastatic cancers such as metastatic breast, prostate, and lung cancers. This includes the identification of biomarkers and the creation of targeted therapies. The expansion of the market is also fueled by extensive R&D activity.
Patients receive treatment to treat cancer, extend life, and improve quality of life. Tumor development is significantly influenced by immune cells. Therefore, inducing immune responses against tumors is a promising therapeutic and preventative strategy. Thus, leading market players are investing in immunotherapy research & development to treat a variety of cancers. For instance, in March 2019, the National Cancer Center Japan and the FUJIFILM Corporation jointly announced the launch of a research project for new cancer immunotherapy using a liposome formulation. Immunotherapy has a greater market penetration due to its efficacy as a treatment, which has improved patient outcomes. Consequently, this is fostering market expansion.
According to International Trade Administration; one in four Singaporeans will be older than 65 by 2030. To prepare for population aging, Singapore is pursuing a national strategy. The Action Plan for Successful Aging from the Ministerial Committee on Ageing includes a wide range of programs, including Seniors' Health Programs, Dementia Friendly Communities, Intergenerational Harmony, and Active Aging. The goal is to make it possible for its citizens to age well, live longer and in better health, take advantage of opportunities for lifelong learning, and actively participate in and engage with their community. The continue aging population in the region raise the need for better healthcare as the old-aged population is more at a risk of getting diseases like cancer. All these factors will uplift the regional metastatic drugs market’s expansion in upcoming years.
The China market dominated the Asia Pacific Metastatic Cancer Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $6,696.5 million by 2030. The Japan market is registering a CAGR of 7.6% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 8.9% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Indication, the market is segmented into Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma & Others. Based on Therapy, the market is segmented into Targeted Therapy, Immunotherapy, Hormonal Therapy and Chemotherapy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Metastatic Cancer Drugs Market is Projected to reach USD 115.6 Billion by 2030, at a CAGR of 7.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, Inc. and Sanofi S.A.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Providers
By Indication
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma & Others
By Therapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- Chemotherapy
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Bristol Myers Squibb Company
- Merck & Co., Inc.
- AstraZeneca PLC
- Novartis AG
- Eli Lilly And Company
- Pfizer, Inc.
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Amgen, Inc.
- Sanofi S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Metastatic Cancer Drugs Market, by Distribution Channel
1.4.2 Asia Pacific Metastatic Cancer Drugs Market, by Indication
1.4.3 Asia Pacific Metastatic Cancer Drugs Market, by Therapy
1.4.4 Asia Pacific Metastatic Cancer Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Approvals & Trials
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2019, Jul – 2023, Apr) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. Asia Pacific Metastatic Cancer Drugs Market by Distribution Channel
5.1 Asia Pacific Hospital Pharmacies Market by Country
5.2 Asia Pacific Drug Store & Retail Pharmacies Market by Country
5.3 Asia Pacific Online Providers Market by Country
Chapter 6. Asia Pacific Metastatic Cancer Drugs Market by Indication
6.1 Asia Pacific Breast Cancer Market by Country
6.2 Asia Pacific Lung Cancer Market by Country
6.3 Asia Pacific Prostate Cancer Market by Country
6.4 Asia Pacific Colorectal Cancer Market by Country
6.5 Asia Pacific Melanoma & Others Market by Country
Chapter 7. Asia Pacific Metastatic Cancer Drugs Market by Therapy
7.1 Asia Pacific Targeted Therapy Market by Country
7.2 Asia Pacific Immunotherapy Market by Country
7.3 Asia Pacific Hormonal Therapy Market by Country
7.4 Asia Pacific Chemotherapy Market by Country
Chapter 8. Asia Pacific Metastatic Cancer Drugs Market by Country
8.1 China Metastatic Cancer Drugs Market
8.1.1 China Metastatic Cancer Drugs Market by Distribution Channel
8.1.2 China Metastatic Cancer Drugs Market by Indication
8.1.3 China Metastatic Cancer Drugs Market by Therapy
8.2 Japan Metastatic Cancer Drugs Market
8.2.1 Japan Metastatic Cancer Drugs Market by Distribution Channel
8.2.2 Japan Metastatic Cancer Drugs Market by Indication
8.2.3 Japan Metastatic Cancer Drugs Market by Therapy
8.3 India Metastatic Cancer Drugs Market
8.3.1 India Metastatic Cancer Drugs Market by Distribution Channel
8.3.2 India Metastatic Cancer Drugs Market by Indication
8.3.3 India Metastatic Cancer Drugs Market by Therapy
8.4 South Korea Metastatic Cancer Drugs Market
8.4.1 South Korea Metastatic Cancer Drugs Market by Distribution Channel
8.4.2 South Korea Metastatic Cancer Drugs Market by Indication
8.4.3 South Korea Metastatic Cancer Drugs Market by Therapy
8.5 Singapore Metastatic Cancer Drugs Market
8.5.1 Singapore Metastatic Cancer Drugs Market by Distribution Channel
8.5.2 Singapore Metastatic Cancer Drugs Market by Indication
8.5.3 Singapore Metastatic Cancer Drugs Market by Therapy
8.6 Malaysia Metastatic Cancer Drugs Market
8.6.1 Malaysia Metastatic Cancer Drugs Market by Distribution Channel
8.6.2 Malaysia Metastatic Cancer Drugs Market by Indication
8.6.3 Malaysia Metastatic Cancer Drugs Market by Therapy
8.7 Rest of Asia Pacific Metastatic Cancer Drugs Market
8.7.1 Rest of Asia Pacific Metastatic Cancer Drugs Market by Distribution Channel
8.7.2 Rest of Asia Pacific Metastatic Cancer Drugs Market by Indication
8.7.3 Rest of Asia Pacific Metastatic Cancer Drugs Market by Therapy
Chapter 9. Company Profiles
9.1 Bristol Myers Squibb Company
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Merck & Co., Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.6 SWOT Analysis
9.3 AstraZeneca PLC
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 SWOT Analysis
9.4 Novartis AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.6 SWOT Analysis
9.5 Eli Lilly And Company
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.6 SWOT Analysis
9.6 Pfizer, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional & Segmental Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.6 SWOT Analysis
9.7 F. Hoffmann-La Roche Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials & Approvals:
9.7.6 SWOT Analysis
9.8 Johnson & Johnson
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental &Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.6 SWOT Analysis
9.9 Amgen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expenses
9.9.5 SWOT Analysis
9.10. Sanofi S.A.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.6 SWOT Analysis
TABLE 1 Asia Pacific Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Metastatic Cancer Drugs Market
TABLE 4 Product Launches And Product Expansions– Metastatic Cancer Drugs Market
TABLE 5 Acquisition and Mergers– Metastatic Cancer Drugs Market
TABLE 6 Approvals & Trials– Metastatic Cancer Drugs Market
TABLE 7 Asia Pacific Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 Asia Pacific Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 9 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 11 Asia Pacific Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Drug Store & Retail Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 13 Asia Pacific Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Online Providers Market by Country, 2023 - 2030, USD Million
TABLE 15 Asia Pacific Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 17 Asia Pacific Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 19 Asia Pacific Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 21 Asia Pacific Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 22 Asia Pacific Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 23 Asia Pacific Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 24 Asia Pacific Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 25 Asia Pacific Melanoma & Others Market by Country, 2019 - 2022, USD Million
TABLE 26 Asia Pacific Melanoma & Others Market by Country, 2023 - 2030, USD Million
TABLE 27 Asia Pacific Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 28 Asia Pacific Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 29 Asia Pacific Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 30 Asia Pacific Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 31 Asia Pacific Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 32 Asia Pacific Immunotherapy Market by Country, 2023 - 2030, USD Million
TABLE 33 Asia Pacific Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 34 Asia Pacific Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 35 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 36 Asia Pacific Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 37 Asia Pacific Metastatic Cancer Drugs Market by Country, 2019 - 2022, USD Million
TABLE 38 Asia Pacific Metastatic Cancer Drugs Market by Country, 2023 - 2030, USD Million
TABLE 39 China Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 40 China Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 41 China Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 China Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 China Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 44 China Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 45 China Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 46 China Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 47 Japan Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 48 Japan Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 49 Japan Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 Japan Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Japan Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 52 Japan Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 53 Japan Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 54 Japan Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 55 India Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 56 India Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 57 India Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 India Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 India Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 60 India Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 61 India Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 62 India Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 63 South Korea Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 64 South Korea Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 65 South Korea Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 South Korea Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 South Korea Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 68 South Korea Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 69 South Korea Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 70 South Korea Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 71 Singapore Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 72 Singapore Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 73 Singapore Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Singapore Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Singapore Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 76 Singapore Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 77 Singapore Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 78 Singapore Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 79 Malaysia Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 80 Malaysia Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 81 Malaysia Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Malaysia Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Malaysia Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 84 Malaysia Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 85 Malaysia Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 86 Malaysia Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 87 Rest of Asia Pacific Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 88 Rest of Asia Pacific Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 89 Rest of Asia Pacific Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 90 Rest of Asia Pacific Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 91 Rest of Asia Pacific Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 92 Rest of Asia Pacific Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 93 Rest of Asia Pacific Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 94 Rest of Asia Pacific Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 95 Key Information – Bristol Myers Squibb Company
TABLE 96 KEY INFORMATION - Merck & Co., Inc.
TABLE 97 KEY INFORMATION – AstraZeneca PLC
TABLE 98 Key Information – Novartis AG
TABLE 99 Key Information – Eli Lilly And Company
TABLE 100 Key Information – Pfizer, Inc.
TABLE 101 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 102 Key Information – Johnson & Johnson
TABLE 103 Key Information – Amgen, Inc.
TABLE 104 Key Information – Sanofi S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 Asia Pacific Metastatic Cancer Drugs Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Metastatic Cancer Drugs Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2019, Jul – 2023, Apr) Leading Players
FIG 7 Porter’s Five Forces Analysis - Metastatic Cancer Drugs Market
FIG 8 Asia Pacific Metastatic Cancer Drugs Market share by Distribution Channel, 2022
FIG 9 Asia Pacific Metastatic Cancer Drugs Market share by Distribution Channel, 2030
FIG 10 Asia Pacific Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 Asia Pacific Metastatic Cancer Drugs Market share by Indication, 2022
FIG 12 Asia Pacific Metastatic Cancer Drugs Market share by Indication, 2030
FIG 13 Asia Pacific Metastatic Cancer Drugs Market by Indication, 2019 - 2030, USD Million
FIG 14 Asia Pacific Metastatic Cancer Drugs Market share by Therapy, 2022
FIG 15 Asia Pacific Metastatic Cancer Drugs Market share by Therapy, 2030
FIG 16 Asia Pacific Metastatic Cancer Drugs Market by Therapy, 2019 - 2030, USD Million
FIG 17 Asia Pacific Metastatic Cancer Drugs Market share by Country, 2022
FIG 18 Asia Pacific Metastatic Cancer Drugs Market share by Country, 2030
FIG 19 Asia Pacific Metastatic Cancer Drugs Market by Country, 2019 - 2030, USD Million
FIG 20 SWOT Analysis: Bristol Myers Squibb Company
FIG 21 Swot Analysis: Merck & Co., Inc.
FIG 22 Swot Analysis: AstraZeneca PLC
FIG 23 SWOT Analysis: Novartis AG
FIG 24 Swot Analysis: Eli Lilly And Company
FIG 25 Recent strategies and developments: Pfizer, Inc.
FIG 26 Swot Analysis: Pfizer, Inc.
FIG 27 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 28 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 29 Swot Analysis: Johnson & Johnson
FIG 30 Swot Analysis: Amgen, Inc.
FIG 31 Swot Analysis: Sanofi S.A.